Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against... 
More about the company
Latest news on CEL-SCI CORPORATION
09/28 CEL SCI CORP : Other Events (form 8-K)
09/27 CEL SCI : NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study
09/27 CEL SCI : Reports Clinical Hold on Head and Neck Cancer Study
09/15 CEL SCI : Reports Monthly Patient Enrollment in August for Its Phase 3 Head and ..
09/15 CEL SCI : Announces Resignation of its Founder for Health Reasons
09/09 CEL SCI : Announces the Closing of Its $5 Million Registered Direct Offering
09/06 CEL SCI : NEW STORY CEL-SCI Announces Resignation of Its Founder for Health Reas..
09/06 CEL SCI : Announces Resignation of its Founder for Health Reasons
09/02 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in August for Its..
09/02 CEL SCI : Reports Monthly Patient Enrollment in August for Its Phase 3 Head and ..
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Geert R. Kersten CEO, CFO, Treasurer, Director & CAO
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION43
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
CELGENE CORPORATION-14.19%79 659
REGENERON PHARMACEUTIC..-25.15%42 787
VERTEX PHARMACEUTICALS..-32.45%21 061
More Results